GlassScriptPhysician profile
Matthew Anthony Mcbride
NPI 1871536920
$33,104.91
in general payments reported to CMS, 2019-2025
31 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $3,915 · 2021: $4,178 · 2022: $13K · 2023: $281 · 2024: $789 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,250.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26,483.24 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,454.91 | 2021 | |
| Allergan, INC. | $410.05 | 2019 | |
| Janssen Scientific Affairs, LLC | $367.26 | 2019 | |
| Medtronic, INC. | $329.16 | 2024 | Interstim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $323.28 | 2019-2022 | |
| Conmed Corporation | $281.09 | 2023 | Conmed Biliary, Conmed Hemostasis, Conmed Generators |
| Takeda Pharmaceuticals U.S.A., INC. | $277.04 | 2021-2022 | |
| Celgene Corporation | $170.87 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $146.12 | 2024 | Voquezna |
| Micro-Tech Endoscopy USA, INC. | $129.28 | 2025 | Lockado |
| Daiichi Sankyo INC. | $110.40 | 2019-2022 | |
| Gilead Sciences, INC. | $92.98 | 2019-2022 | |
| Janssen Biotech, INC. | $74.95 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $65.49 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $57.39 | 2020-2022 | |
| Qol Medical, LLC | $45.58 | 2021-2022 | |
| Pfizer INC. | $40.46 | 2019 | |
| Intercept Pharmaceuticals, INC. | $37.05 | 2019-2021 | |
| Shire North American Group INC | $36.59 | 2019 | |
| Mallinckrodt Hospital Products INC. | $29.81 | 2022 | |
| Ucb, INC. | $28.38 | 2019 | |
| Ironwood Pharmaceuticals, INC | $26.63 | 2019-2020 | |
| Ardelyx, INC. | $25.30 | 2022 | |
| Amgen INC. | $24.93 | 2021-2022 | |
| Genzyme Corporation | $21.11 | 2021 | |
| Genentech, INC. | $15.56 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.